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Rapport de Synthèse 
Limited Sampling Strategies for Monitoring 
Tacrolimus in Pediatric Liver Transplant Recipients 
Ce travail de recherche a été réalisé dans le laboratoire de pharmacologie 
clinique, au Centre Hospitalier Universitaire Sainte-Justine, à Montréal. 
C'est une étude rétrospective basée sur le suivi thérapeutique du Tacrolimus 
prescrit chez les enfants après transplantation hépatique. Ce suivi est nécessaire 
car le Tacrolimus possède une importante variabilité pharmacocinétique inter et 
intra-individuelle ainsi qu'un index thérapeutique très étroit. Actuellement, 
l'individualisation des doses prescrites est basée sur la mesure de la 
concentration de base du médicament dans le sang (C0), mais des études 
récentes montrent que cette mesure ne reflète pas précisément l'exposition du 
Tacrolimus dans l'organisme chez les enfants. Le meilleur reflet de cette 
exposition est la mesure de l'aire sous la courbe (AUC). Cependant, cette 
dernière implique la mesure de multiples concentrations tout au long de 
l'intervalle entre 2 doses de médicament (Tacrolimus: 12 heures) ce qui est 
long, cher et impraticable en ambulatoire. De nouvelles méthodes utilisant un 
nombre limité de prélèvements ont donc été développées pour prédire au mieux 
cette AUC. Ce sont les "Limited sampling strategies" ou LSS. La plupart de ces 
LSS pour le Tacrolimus ont été développées et validées chez des patients 
transplantés adultes et leur application directe chez les transplantés pédiatriques 
n'est pas possible en raison de différences importantes au niveau des paramètres 
pharmacocinétiques du médicament entre ces deux populations. 
Aussi, le but de ce travail était de développer et valider, pour la première fois, 
des LSS chez les enfants transplantés hépatiques. Pour cela, une analyse de 36 
profils pharmacocinétiques de 28 patients transplantés hépatiques âgés de 0.4-
18.5 ans a été effectuée. Tous les profils ont été réalisés au Centre Hospitalier 
Universitaire Sainte-Justine entre janvier 2007 et janvier 2009. 
Les LSS comportant au maximum 4 mesures de concentration ont été 
développées en utilisant une analyse de régression multiple. Parmi tous les 
modèles obtenus, cinq ont été sélectionnés sur la base de critères précis puis 
validés selon la méthode décrite par Sheiner et Beal. 
Les résultats montrent que ces cinq modèles peuvent prédire l'AUC du Tacrolimus 
avec une précision cliniquement acceptable de ± 15% alors que la Co présente la 
plus faible corrélation avec l'AUC. 
En conclusion, cette étude confirme que la Co ne permet pas de prédire de 
manière efficace l'exposition du Tacrolimus dans l'organisme dans notre 
population de patients pédiatriques contrairement aux LSS analysées qui offrent 
une méthode pratique et fiable. Par ailleurs, en permettant d'obtenir une 
estimation précise et simplifiée de l'AUC complète du Tacrolimus chez les 
patients, ces LSS ouvrent la porte à de futures études prospectives visant à 
mieux définir l'AUC cible du médicament et à déterminer si le suivi basé sur la 
mesure de l'AUC est plus efficace et plus sûr que celui basé sur la mesure de la 
Co. 
ORIGINAL ARTICLE 
Limited Sampling Strategies for Monitoring Tacrolimus in 
Pediatric Liver Transplant Recipients 
Jean-Romain Delaloye, MD, *f Nastya Kassir, PharmD,ff Anne-Laure Lapeyraque, MD, f§ 
Fernando Alvarez, MD, PhD, 1f Michel Lallie1; MD,* Mona Beaunoye1; MD,* Line Labbé, PhD,f 
Yves Théorêt, PhD, fil** and Catherine Litalien, MDf**ff 
Objective: To develop and validate limited sampling strategies 
(LSSs) for tacrolimus in pediatric li ver transplant recipients. 
Methods: Thirty-six 12-hour pharmacokinetic profiles from 28 
pediatric liver transplant recipients (0.4-18.5 years) were collected. 
Tacrolimus concentrations were measured by immunoassay and area 
under the curve (AUC0_ 12) was determined by trapezoidal mie. LSSs 
consisting of 1, 2, 3, or 4 concentration-time points were developed 
using multiple regression analysis. Eight promising models (2 per 
category) were selected based on the following criteria: 1?- 2: 0.90, 
inclusion of trough concentration ( C0), and time points within 4 hours 
postdose. The predictive performance ofthese LSSs was evaluated in 
an independent set of data by measuring the mean prediction error 
and the root mean squared prediction error . 
Results: Five models including 2-4 time points predicted AUC0_ 12 
with a ± 15% error limit. Bias (mean prediction error) and precision 
(root mean squared prediction error) ofLSS involving C0, Ci, and C4 
(AUCpredicted = 9.30 + 3.69 X Co+ 2.19 X C1 + 4.69 X C4) were 
-4.98% and 8.29%, respectively. Among single time point LSSs, the 
mode! using C0 had a poor correlation with AUC0_12 (1?- = 0.53), 
whereas the one with C4 had the highest correlation with tacrolimus 
exposure (1?- = 0.84). 
Conclusions: Trough concenh·ation is a poor predictor of tacroli-
mus AUCa-12 in pediah·ic liver transplant recipients. However, LSSs 
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using 2-4 concentration-time points obtained within 4 hours post-
dose provide a reliable and convenient method to predict tacrolimus 
exposure in this population. The proposed LSSs represent an im-
portant step that will allow the undertaking of prospective trials 
aiming to better define tacrolimus target AUC in pediatric liver 
transplant recipients and to determine whether AUC-guided moni-
toring is superior to C0-based monitoring in terms of efficacy and 
safety. 
Key Words: tacrolimus, therapeutic drug monitoring, pediatrics, liver 
transplantation, limited sampling strategies 
(Ther Drug Monit 2011 ;33:380-386) 
INTRODUCTION 
Tacrolimus (Prograf, Fujisawa Healthcare Inc) is the 
most prescribed immunosuppressive agent in pediatric solid 
organ transplant recipients; the proportion of pediatric patients 
receiving tacrolimus increased from 14.5% in 1997 to 63.2% 
in 2006. 1 As with cyclosporine, tacrolimus inhibits calcineurin 
and blocks the transcription of cytokines that drive the 
proliferative T-cell response, particularly interleukin-2. 
Therapeutic drug monitoring has become a standard of 
care for tacrolimus dosing optimization because of its sig-
nificant interindividual and intraindividual phannacokinetic 
(PK) variability and its narrow therapeutic index. Although 
whole blood trough concentration (C0) is the current method 
used to guide dose individualization, measurement of C0 o:ften 
fails to refiect total drug exposure for drugs with variable 
bioavailability and unpredictable elimination characteristics 
such as tacrolimus. In such instances, systemic drug exposure 
may be best refiected by the area under the concentration-fane 
curve (AUC). Many pediatric studies have shown that the 
relationship between tacrolimus C0 and AUC is highly variable, 
with correlation (r2) ranging from 0.30 to 0.88.2- 13 Addition-
ally, controversies remain about the relationship between C0 
and clinical outcomes. 14•15 In liver transplantation, although 
a number of studies have shown a significant correlation 
between C0 and tacrolimus nephrotoxicity and neurotoxicity, 
reports failed to demonstrate a linear relationship between 
tacrolimus C0 and the development of gra:ft rejection. 16- 18 
In adult kidney recipients, Undre et al19 reported a sig-
nificant correlation between low systemic exposure oftacrolimus 
and acute rejection, whereas Mahalati et al20 demonstrated that 
AUC was a better predictor of clinical outcomes than C0 for the 
Ther Drug Monit • Volume 33, Number 4, August 2011 
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related calcineurin inhibitor cyclosporine. However, AUC-based 
monitoring, which implies the measurement of multiple 
concentration-tiine points over the entire dosing interval, is tiine 
consuming, expensive, and o:ften impractical for routine clinical 
practice, especially in the pediatric population.21 Alternatively, 
AUC can be predicted using the limited sampling strategy (LSS) 
approach, which has been developed so that a restricted number 
of sampling tiines can be used. Most LSSs for tacrolimus have 
been derived from adult transplant recipients,22- 26 and their direct 
application in children may not be feasible because of different 
tacrolimus PKs.27 In the pediatric population, 3 studies have 
proposed LSSs to estimate tacrolimus exposure2•3•28; none of 
these LSSs have been validated in an independent set of 
data.21 •29•3° Furthennore, 2 of these trials2•3 involved stable renal 
transplant patients and, as such, their use in other types of 
transplantation is not recmmnended because LSSs should only be 
applied to the patient population for which they have been 
validated.21 The third trial dealt with children who unde1went liver 
transplantation but provided only limited information with regard 
to the population studied and the methodological approach 
used.28 
The aim of this study was to develop and validate LSSs 
for tacrolimus in pediatric liver transplant recipients. 
MATERIALS AND METHODS 
Patients and Study Design 
This is a retrospective study analyzing 12-hour PK 
profiles perfonned in the pediatric liver transplant population 
of the Centre Hospitalier Universitaire Sainte-Justine (Mon-
treal, Canada) between January 2007 and January 2010. The 
study was approved by the Institutional Research Ethics 
C01mnittee. Ali liver transplant recipients :::; 18 years of age 
who unde1went full tacrolimus PK profile as part of their 
clinical care were considered to be eligible for inclusion. 
Exclusion criteria included patients not receiving oral 
tacrolimus twice daily and those for whom a full PK profile 
was not obtained at least 3 days a:fter receiving the same dose 
of tacrolimus. 
Tacrolimus was administered as a capsule or suspension 
(5 mg/mL) without any food intake recommendation. The 
dosage was adjusted by the liver transplant team to keep 
tacrolimus C0 within a suggested target range of 5-15 ng/mL 
according to thne posttransplantation and concomitant ümnu-
nosuppression. However, the measurement of AUC0_ 12 was 
requested in some specific situations including at or around 
patient discharge; when nephrotoxicity occurred despite C0 
levels within the target range; when important intraindividual 
C0 variability occurred in the absence of dose modification; 
and at mycophenolate mofetil initiation. 
Whenever available in the medical chatt, the following data 
were recorded for each patient: demographic parameters, type of 
liver transplantation, underlying diagnosis, tiine posttransplanta-
tion at which the PK profile was perfonned, tacrofünus dosing 
regünen and fonnulation, concomitant itmnunosuppression, 
blood chemistry (liver and renal function tests, hemoglobit1, 
hematoc1it, and albumin), and presence of clinically relevant 
CYP3A4 and/or P-glycoprotein inducer or inhibitor. 
© 2011 by Lippincott Williams & Wilkins 
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Sample Collection and Analytical Methods 
Serial blood samples were collected in ethylenediami-
netetraacetic acid-containing vacutainers ümnediately before 
tacrolimus administration (C0), and a:fter 0.5 (C0.5), 1 (C1), 1.5 
(C1.5), 2 (C2), 3 (C3), 4 (C4), 8 (C8), and 12 (C12) hours. 
Tacrolimus whole-blood concentrations were determined 
using the microparticle enzyme ümnunoassay IMx (Abbott 
Laboratories, Abbott Park, IL). The lower and upper limits of 
detection were 1.5 and 30 ng/mL, respectively. The between-
run coefficients of variation were 14.10% at 5 ng/mL, 11.15% 
at 11 ng/mL, and 10.21 % at 22 ng/mL. 
Pharmacokinetic and Statistical Analyses 
PK parameters were estimated using noncomparhnental 
methods. Tacrolimus peak concentration (Cmax), time to reach 
Cmax (T,nax), and Co, were determined for each patient from 
direct data observation. Observed tacrolimus AUC (AUC0_ 12) 
was calculated using the linear trapezoidal rule (S-plus 8.1, 
Insightful Corporation, Seattle, WA). 
PK data were randomly split into 2 equal groups: 
a training group and a validation group. In the h·aining group, 
a multiple regression analysis was used to determine the 
relationship between observed tacrolimus AUC0_ 12 ( dependent 
variable) and the concentrations at various titne points 
(independent variable or predictor). This was carried out 
using the best-subset regression in conjunction with the 
stepwise fmward selection technique. This method consists of 
starting with an equation with no predictor, trying them out 
one by one sequentially, and calculating the coefficient of 
determination for each equation (r2). Multiple linear re-
gression models were developed in which 1, 2, 3, or 4 
concentration-time points were used as predictors. All 
possible equations were derived and the 2 best regression 
models using 1, 2, 3, and 4 predictors were identified based on 
the following criteria: r2 2: 0.90, inclusion of C0, and time 
points within 4 hours posttacrolimus administration. 
Equations were then validated in an independent set of 
patients, the validation group. The latter was used to estimate 
the predictive perfonnance of the regression models developed 
in the training group. As suggested by Sheiner and Beal,30 2 
error indices, the mean prediction error (ME) and the root 
mean squared prediction error (RMSE), were calculated to 
evaluate bias and precision, respectively. Their relative values, 
expressed as percentages, were also calculated. The following 
equations were used: 
1 N 
ME=-I (Pred- Obs), 
Ni=! 
1 N 
MSE =- I (Pred - Obs)2 , 
Ni=! 
RMSE=VMSE, 
ME(%)=~ I (Pred - Obs) XlOO, 
Ni=! Obs 
381 
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RMSE(%) = ~I (Pred~Obs)2 XlOO. 
Ni=! 0 s 
where Pred is the predicted value of AUC~1 2' Obs is the 
AUC0_12 observed value, MSE is the mean squared prediction 
error, and N is the number of patients. A 95% confidence 
interval (CI) was calculated for each parameter. In addition, the 
predictive perfonnance of the LSSs was tested by the method 
ofBland and Altman.31 Finally, an approach based on Cis was 
used to compare the predictive performance of the different 
regression models.30 This consisted of computing the 
difference in MSEs (L'.lMSE) and MEs (LlME) between the 2 
models compared and calculating their Cis. If the CI did not 
include zero, the model with the smaller MSE or ME was 
considered significantly more precise or less biased, re-
spectively. On the other hand, when the CI included zero, the 
MSE or ME difference was considered not significant. Clinical 
and PK data are presented as mean ± SD or median (range). 
Comparisons between patient characteristics and PK 
parameters of the training and validation groups were 
performed using the unpaired t-test for normally distributed 
data and the Wilcoxon Rank-Sum test for skewed data. 
Statistical significance was defined at P value s0.05. All 
statistical analyses were performed using S-plus 8.1, SAS 9.2 
(SAS Institute Inc, Cary, NC), and GraphPad Prism 5.0 
(GraphPad Software, San Diego, CA). 
RESULTS 
A total of 42 full PK profiles obtained from 31 liver 
transplant recipients were available for this study. Thirty-six 
profiles from 28 patients (15M/13F) aged between 0.4 and 
18.5 years were included. Six profiles from 3 patients were 
excluded because either they were not obtained under steady-
state conditions (n = 3), or they were obtained while patients 
were receiving tacrolimus 3 tünes a day. The indications for 
whole liver (10 patients) or cut-down liver (18 patients) 
transplantation were biliary atresia (n = 11 ), tyrosinemia (n = 7), 
North American Indian childhood cirrhosis (n = 2), fulminant 
hepatitis (n = 2), Alagille syndrome (n = 2), histiocytosis (n = 2), 
sclerosing cholangitis (n = 1), and autoiimnune hepatitis (n = 1). 
Patient characteristics are smmnarized in Table 1. As 
shown, the 36 PK profiles were equally divided in the training 
and validation groups. One patient with 3 full measurements of 
AUC0_12 was included in both groups, with 2 profiles in the 
training group and 1 in the validation group. The patient 
characteristics were not statistically different between the 2 
groups, except for 2 liver parameters (alanine aminotransfer-
ase and )'-glutamyltranspeptidase ). 
Concomitant use of corticosteroids, which may induce 
CYP3A isoenzyme, was present for 22 PK profiles (61.1 %). In 
about half of the profiles (52.8%), the patients were receiving 
1 or 2 drngs known as potential CYP3A4 and/or P-glycoprotein 
inhibitors: amlodipine and lansoprazole (n = 6), amlodipine 
and enalapril (n = 1 ), amlodipine (n = 9), lansoprazole (n = 2), 
and diltiazem (n = 1). 
Tacrolimus concentration~time profiles and PK param-
eters (Fig. 1 and Table 2, respectively) exhibited a high degree 
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of between-individual variability. When PK parameters were 
nonnalized for a tacrolimus dose of 0 .1 mg/kg, no significant 
difference was observed between the training and validation 
groups (P = 0.73, 0.87, and 0.44 for AUCo-12, Co, and Cinax, 
respectively ). 
LIMITED SAMPLING 
STRATEGY DEVELOPMENT 
Two hundred fifty-five regression equations were 
developed to predict tacrolimus AUC0_12 using a maximum 
of 4 different concentration-time points. Among these 
equations, 5 were identified as best regression models based 
on the predefined selection criteria (models 1-5; Table 3). For 
comparison purposes, 4 equations that did not meet these 
criteria (models 6--9) are also presented. Among the 3 single 
concentration-time point equations shown, those involving C0 
and C4 had the poorest e· = 0.53) and the highest (r2 = 0.84) 
correlation with AUC0_12, respectively. 
LIMITED SAMPLING STRATEGV VALIDATION 
The predictive performance of the selected LSSs is 
sununarized in Table 4. The %RMSE (precision) of the 5 
regression equations and their Cis were <15%. The %ME 
(bias) was also < 15%, although all the models tended to 
underestimate tacrolimus AUC~12 . The relative performance 
of the different LSSs is shown in Table 5. For 3 out of the 4 
regression models using 3 or 4 concentration-time points 
(models 1-3), precision and bias were significantly better than 
for the model using 2 point equation (model 5). The fourth 
model using 3 tüne points (model 4) was significantly more 
precise than model 5, but there was no difference in bias 
between the 2 models. Finally, no significant difference was 
observed between the predictive capacity of LSSs involving 3 
and 4 concentration-fane points. 
Figures 2A and B depict the linear correlation of 
observed AUC0_12 and AUC0_12 predicted by mode! 3 (C0-C1-
C4) and mode! 5 ( C0-C4), respectively. Figures 2C and D show 
the Bland and Altman analysis of the paired samples for both 
models, with the average of predicted and observed AUC0_12 
ranging from 83.6 to 305.0 ng·hlmL. In accordance with 
%ME, the predicted AUC~12 was lower than the observed 
AUC0_12, with a bias of -5.4% for model 3 (Fig. 2C) and 
-10.5% for model 5 (Fig. 2D). 
DISCUSSION 
This is the first study on the development and 
validation ofLSSs for the prediction oftacrolimus AUC0_12 
in pediatric liver transplant recipients. Five LSSs using 2-4 
concentration-tüne points obtained within 4 hours of 
tacrolinms dosing and including C0 have been developed 
and provide an accurate and convenient method to predict 
tacrolimus AUC0_12 in this population. Ail the 5 models 
predicted tacrolimus AUC0_12 with a ± 15% prediction 
error lünit; this is a clinically acceptable range because it 
represents the deviation from the observed AUC that 
usually initia tes dosage adjustment. 29·32·33 
© 2011 by Lippincott Williams & Wilkins 
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TABLE 1. Summary of Patient Characteristics on the Day of the PK Profile [Results Expressed as Number or Mean ± SD or 
Median (Range)] 
Variable Training Group (18 Profiles) Validation Group (18 Profiles) p 
Age (yrs) 
Weight (kg) 
Time after transplantation (mos) 
Tacrolimus dose (mg·kg- 1 ·d-1 )* 
Tacrolimus formulationst 
Suspension (5 mg/mL) 
Capsule 
Concomitant immunosuppressive agents 
None 
Corticosteroids 
Corticosteroids + MMF 
MMF 
AST (U/L) 
ALT (U/L) 
GGT (U/L) 
AP (U/L) 
Bilirubine (µ,11101/L) 
Hb (g/dL) 
12.0 (0.4--16.9) 
34.7 (4.5--61.3) 
24.1 (0.5-166.2) 
0.11 (0.05--0.54) 
7 
11 
7 
0 
10 
31 (16--304) 
45 ::!:: 27 (17-125) 
51 (8-26l)t 
168 (49-448) 
10 (4-25H 
120 ::!:: 21 (83-151) 
2.9 (0.6--18.5) 
17.3 (6.2-59.1) 
4.2 (0.5-185.5) 
0.19 (0.05-0.42) 
11 
6 
0 
9 
6 
3 
47 (24--148) 
93 ::!:: 69 (14--249) 
98 (13-886) 
130 (66--567)* 
11 (5-110) 
120 ::!:: 16 (84--143) 
0.20 
0.58 
0.46 
0.44 
Hct (%) 
Serum albumin (g/L) 
Serum creatinine (mg/dL) 
0.34 ::!:: 0.05 (0.25-0.44)§ 
35 ::!:: 3 (32-40)§ 
0.36 ::!:: 0.04 (0.26--0.43)* 
36 ::!:: 4 (27-43)* 
0.06 
0.01 
0.02 
0.53 
0.84 
0.92 
0.48 
0.66 
0.23 
*Given twice a day. 
tData available for 17 profiles in the validation group. 
*Data available for 17 profiles. 
§Data available for 13 profiles. 
0.5 ::!:: 0.2 (0.3--0.9) 0.4 ::!:: 0.3 (0.1--0.9) 
ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate aminoh·ansferase; GGT, ')'-glutamyltranspeptidase; Hb, hemoglobin; Hct, hematocrit; MMF, mycophenolate 
mofetil. 
Among single concentration-time point LSSs, regres-
sion model using C0 had a poor correlation with AUC0_ 12 (r2 = 
0.53), whereas the one with C4 had the highest correlation with 
tacrolimus exposure (r2 = 0.84). This is in accordance with 
other adult and pediatric studies that have shown C0 to be 
60 
0-+-~~~~~~~~~~~~~~~~~....-~....---. 
0 2 4 6 8 10 12 
Time (hours) 
FIGURE 1. Tacrolimus concentrations as a function of time 
plotted for the 36 PK profiles (training group, solid lines; 
validation group, dashed gray lines). 
© 2011 by Lippincott Williams & Wilkins 
a poor predictor of tacrolimus exposure in solid organ 
transplantation. 2•3•6•8• 14•34•35 
LSSs developed in this study involved a limited number 
of blood samples within a short period of tüne after drug 
administration, originally suggested by Ting et al. 21 This 
method is convenient for bath the patient and the clinician and 
is financially acceptable for the institution. The inclusion of 
predose measurement in the equations was a deliberate choice. 
Indeed, C0 allows checking for compliance, helps identify 
patients with high tacrolimus clearance, and is a routinely used 
marker by clinicians. 29•36 
TABLE 2. PK Parameters of Tacrolimus After Oral 
Administration in Pediatric Liver Transplant Recipients [Results 
Expressed as Mean ± SD or Median (Range)] 
Training Validation 
Parameter Group (n = 18) Group (n = 18) p 
Co (ng/mL) 7.3 ::!:: 2.8 (2.9-13.6) 9.7 ::!:: 3.5 (4.7-18.3) 0.87* 
Cmax (ng/mL) 12.1 (5.6--32.1) 17.9 (9.8-52.5) 0.58* 
Tmax (h) 2.5 (0.7-4.0) 1.5 (1.0-6.0) 0.11 
AUC0 12 (ng·hlmL) 114.0 (51.4--245.0) 141.2 (94.0-310.7) 0.70* 
*For PK parameter nonnalized for a tacrolimus dose of 0.1 mg/kg. 
AUCa-12, area under the concentration-time curve from 0 to 12 hours postdose; C0, 
trough concentration; Cmax, peak concentration; n, number of PK profiles; Tmax, time to 
reach Cmax· 
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TABLE 3. Regression Equations for Predicting Tacrolimus AUC0_12 in Pediatric Liver Transplant Recipients With the Associated 
Coefficient of Determination (r) 
Model Time points Regression Equation ,J. 
1 Co, C1o C2, C4 AUCP = 9.15 + 3.65 X C0 + 1.81 X C1 + 0.51 X C2 + 4.55 X C4 0.99 
2 Co, Co.s, C2, C4 AUCP = 9.51 + 3.52 X C0 + 1.27 X C0.5 + 1.52*C2 + 4.29 X C4 0.99 
3 C0 , C1o C4 AUCP = 9.30 + 3.69 X Co+ 2.19 X C1 + 4.69 X C4 0.99 
4 C0 , Ci.5 , C4 AUCP = 9.14 + 4.11 X Co+ 1.69 X Cl.5 + 4.67 X C4 0.98 
5 Co, C4 AUCP = 17.93 + 5.79 X Co+ 4.71 X C4 0.94 
6 Co, C2 AUCP = 18.56 + 6.97 X C0 + 4.05 X C2 0.71 
7 C4 AUCP = 45.19 + 5.87 X C4 0.84 
8 C2 AUCP = 44.33 + 6.01 X C2 0.58 
9 Co AUCP = 36.24 + 11.68 X Co 0.53 
AUCr, predicted area under the concentration-time curve. 
In pediatric organ transplantation, data published 
regarding LSSs are scarce. One report involving 14 liver 
recipients has suggested a 3 concentration-time points LSS 
(C1-C4-C8), but without evaluation of its predictive perfor-
mance.28 In renal transplant recipients, 2 studies2•3 have 
proposed LSSs, although with inconvenient sampling tiines 
for an outpatient setting ( C6) and no validation with an 
independent set of data.21 •29·30 Both studies showed a weak 
correlation between observed AUC and C0 (r2 = 0.36 and 12 = 
0.56) and among single concentration-time point, the best 
c01Telation was observed with C4 • These observations are in 
agreement with our results. 
As in children, limited data are available in adult liver 
transplant recipients. Dansirikul et al34 developed LSSs based on 
single tune point. In their study, AUCo-D was assumed to be 
a stmogate of the full tacrolimus AUC (AUC0--12) and was used 
for LSS analysis. The authors showed that regression equations 
with sampling tune at 2, 4, or 5 hours postdose rather than C0 
were superior in predicting tacrolimus exposure (AUCO-D). 
However, only the LSS model involvu1g C5 was properly 
validated with ajacklmife technique. In renal transplant patients, 
numerous LSSs have been published over the last decade 
although proper validation was often lacking.23•33•37- 39 More 
recently, Miura et al40 developed and validated LSSs for the 
simultaneous estunation of AUC of tacrolimus and mycophe-
nolic acid in this population. Similar to our findings, they 
reported that combinations of 2 or 3 concentration-tune points 
including C0 and C4 ( C0-C4 and C0-CrC4) provided reliable 
estunation of tacrolimus AUC0_12; however, the best LSS for 
sunultaneous prediction of the 2 ümnunosuppressive agents 
included C2, C4 , and C9• These results are not surprising 
considering the enterohepatic circulation of mycophenolic acid 
glucuronides, which causes a secondary plasma peak of 
mycophenolic acid. 
The LSSs developed in this study showed good 
predictive perfonnance in an independent validation group, 
despite high heterogeneity of the studied population in tenns 
of demographic and clinical characteristics, tüne posttrans-
plantation, and shape of PK profiles. This increases the 
likelihood that these LSSs will be used in various clinical 
settings. Additionally, in an "intention" to be highly rep-
resentative of clinical reality, outlier PK profiles were not 
removed even if this was associated with the potential risk of 
underestimating the predictive performance of the LSSs. 
Another strength of these LSSs is the ease with which they 
could be applied by health care professionals; this is in contrast 
with LSSs derived from Bayesian analysis where users require 
more extensive training and specialized software programs. 
This study has some lünitations that deserve finiher 
c01mnents. Ting et al21 recently suggested that LSS should be 
applied only on transplant patient populations that are 
comparable with the population used to develop the LSS. As 
such, the predictive power of the LSSs rep01ied in this study 
cannot be guaranteed for patient populations other than pedia1:ric 
liver transplant recipients. By opposition to Bayesian-derived 
LSSs, LSSs developed with a multiple regression approach are 
less flexible in the sampling titne wherein collection of samples 
at exact tunes is necessary.41 hmnunoassays may overestimate 
tacrolimus concentrations compared with those estünated by 
high-performance liquid chromatography methods, due to 
crossreactivity with tacrolünus metabolites. 15 Thus, caution 
should be exercised in the application of the proposed LLSs if 
tacrolimus concentrations are measured with analytic techniques 
different from the specific immunoassay used in this study. 
TABLE 4. Evaluation of the Predictive Performance of LSSs to Estima te Tacroli mus AUC0_ 12 in Pediatric Liver Transplant Recipients, 
Mean (95% Cl) 
Models 
2 
3 
4 
5 
384 
Time Points 
Co, C1, C2, C4 
Co, Co.s, C2, C4 
C0, C1, C4 
C0 , Ci.5 , C4 
Co, C4 
RMSE (ng/mL) 
11.71 (6.97-15.02) 
12.58 (8.50-15.63) 
12.03 (6.59-15.68) 
15.54 (9.08-20.01) 
23.89 (14.25-30.65) 
ME (ng/mL) 
-7.77 (-12.25 to -3.28) 
-8.74 (-13.37 to -4.11) 
~7.91 (-12.55 to -3.28) 
-10.68 (-16.46 to -4.91) 
-18.06 (-26.06 to -10.05) 
RMSE (%) 
8.15 (3.22-11.07) 
8.48 (4.25-11.22) 
8.29 (3.29-11.28) 
9.35 (5.60-11.98) 
11.77 (8.65-14.22) 
ME(%) 
-5.07 (-8.34 to -1.81) 
-6.15 (-9.14 to -3.16) 
-4.98 (-8.37 to -1.59) 
-6.75 (-10.06 to -3.44) 
-9.80 (-13.14 to -6.46) 
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TABLE 5. Relative Performance of the 5 Different Models, 
Mean (95% Cl) 
Models* il MSE (ng2/mL2)t il ME (ng/mL)t 
1 versus 2 -21.17 ( -70.02 to 27 .69) 0.97 (-1.90 to 3.85) 
1 versus 3 -7.54 (-27.82 to 12.74) 0.14 (-1.21to1.49) 
1 versus 4 -104.25 (-236.95 to 28.44) 2.91 ( -1.84 to 7 .67) 
1 versus 5 -433.76 (-785.75 to -81.77) 10.29 (2.54 to 18.03) 
2 versus 3 13.63 (-48.76 to 76.02) -0.83 (-4.80 to 3.14) 
2 versus 4 -83.09 (-237.42 to 71.24) 1.94 (-3.87 to 7.75) 
2 versus 5 -412.60 (-751.08 to -74.11) 9.31 (0.82 to 17.81) 
3 versus 4 -96.71 (-233.49 to 40.07) 2.77 (-2.38 to 7.92) 
3 versus 5 -426.22 (-776.36 to -76.09) 10.15 (2.87 to 17.43) 
4 versus 5 -329.51 (-645.32 to -13.70) 7.37 (-0.63 to 15.38) 
*Model 1: C0-C1-C,-C4; mode! 2: C0-C0.5-C2-C4; mode! 3: C0-C1-C4; mode! 4: 
C0-C1.5-C4; mode! 5: C0-C4. 
tMSE for each mode! was as follows: mode! 1, 137.13; mode! 2, 158.29; mode! 3, 
144.66; mode! 4, 241.38; mode! 5, 570.89. 
*ME for each mode! is reported in Table 4. 
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Limited Sampling Strategies for Monitoring Tacrofimus 
Even though the evaluation of the relative performance 
of the 5 LSSs has shown that 3 and 4 concentration-time 
point LSSs were statistically more precise and less biased 
than the one using 2 tîtne points, all the equations can be used 
with confidence. Therefore, it is the ultimate choice of clin-
icians to decide which model to use according to the desired 
level of precision, balanced with the costs and feasibility in 
clinical practice. 
CONCLUSIONS 
Trough concentration is a poor predictor of tacrolimus 
AUC0_ 12 in pediatric liver transplant recipients. However, 
LSSs using 2-4 concentratîon-time points obtained within 
4 hours oftacrolimus dosing have been developed and provide 
a reliable and convenient method to predict tacrolimus 
exposure in this population. By facilitatîng the accurate 
measurement of tacrolimus full AUC, the proposed LSSs 
represent an important step that wîll allow the undertaking of 
350 
300 
:::J 
.§ 250 
.r; 
• Ol 
s 200 
N 
0 
0 150 
::::> 
<( 
"O 
~ 100 
o.. 
50 
0 
B 
~ 
~ 10% 
(]) 
Ol 
~ (]) 
> ~ 0% 
('::; 
J 
::::> 
<( -10% 
.2 
0 
1 
N 
6 -20% 
0 
::::> 
0 50 
Madel 5: C0-C4 
r2= 0.94 
100 150 200 250 
ObsAUC0_12 (ng*h/ml) 
•• 
300 350 
Model 5: Co-C4 
-------------------------iiiëan+2*s-o:3.9% 
. \ 
• 
• 
• 
• 
-------------~----------------------
• 
mean: -10.5% 
• • 
• • • 
• • 
• 
------------------------mean-::2•so:22s.0% =â 
~ e:, -30%+-~~~~..-~~~~..--~~~--,.--~~~--. 
0 100 200 300 400 
D Average of predAUC0_12 and obsAUC0_12 (ng*h/ml) 
FIGURE 2. Correlation between the observed AUC0-i2 (ObsAUC0-i2) and the predicted AUC0-12 (PredAUC0-i 2) of tacrolimus calculated 
with the equations of mode! 3 (A) involving 3 concentration-time points (C0-Ci-Ci) and mode! 5 (B) involving 2 concentration-time 
points (C0-C4), respectively. Bland and Altman analysis testing agreement between tacrolimus ObsAUC0-i2 and PredAUC0-12 calculated 
with the equations of mode! 3 (C) involving 3 concentration-time points (Co-Ci-Ci) and model 5 (D) involving 2 concentration-time 
points (C0-C4), respectively. 
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prospective trials aiming to better define tacrolimus target 
AUC in pediatric liver transplant recipients and to determine 
whether AUC-guided monitoring is superior to C0-based 
monitoring in tenns of efficacy and safety. 
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